Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis

INTRODUCTION: The terminal complement C5 inhibitor ravulizumab has a long elimination half-life, allowing maintenance dosing every 8 weeks. In the 26-week, double-blind, randomized, placebo-controlled period (RCP) of the CHAMPION MG study, ravulizumab provided rapid and sustained efficacy and was we...

Descripción completa

Detalles Bibliográficos
Autores principales: Vu, Tuan, Ortiz, Stephan, Katsuno, Masahisa, Annane, Djillali, Mantegazza, Renato, Beasley, Kathleen N., Aguzzi, Rasha, Howard, James F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10188401/
https://www.ncbi.nlm.nih.gov/pubmed/36890354
http://dx.doi.org/10.1007/s00415-023-11617-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10188401/
https://www.ncbi.nlm.nih.gov/pubmed/36890354
http://dx.doi.org/10.1007/s00415-023-11617-1

Ejemplares similares